A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."
U.K. antitrust watchdogs are targeting Concordia and its pricing for liothyonine, a thyroid drug that now costs 57 times more than it did in 2006.
Pfizer is in a tug of war with several states that intend to use some of its drugs to carry out executions.
Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services makes its way into law.
Two of Roche's newest drugs—including the just-approved hemophilia therapy Hemlibra—racked up data that bolster their case for $1 billion-plus sales.
One RBC Capital Markets analyst sees lots of reasons Allergan should break up. A women’s health sale that could bring in billions is just one of them.
With all eyes fixed on Monday's vote for the European Medicines Agency relocation, Milan and Amsterdam emerged as top picks.
Biocon has resolved FDA concerns about a plant in India, setting it and Mylan up to potentially win FDA approval for the first Herceptin biosimilar.
Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is reportedly initiating settlement talks.
Atopic dermatitis awareness is again at the center of a Sanofi and Regeneron skin health campaign.